{"generated":"2026-10-25","inputs":{"factcheck":"2026-10-12","trialChanges":"2026-10-12","fda":"2026-10-14","regional":"2026-10-14"},"proposals":[{"kind":"regulatory-event","confidence":"high","entityId":"rituximab","entityName":"Rituximab","entityKind":"drug","route":"/drugs/rituximab/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"0 events; none dated 2026-09-29","proposed":"{ date: \"2026-09-29\", type: \"approval\", region: \"US\", note: \"RIABNI (RITUXIMAB-ARRX): Bioequivalence\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761140\" }","evidence":"AMGEN INC · SUPPL 5 · Bioequivalence","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761140","detected":"2026-10-14","id":"regulatory-event:rituximab:regulatoryevents:-date:-2026-09-29-type:-approval-region:-us-note:-riabni-rituximab-arrx-:-bioequivalence-source:-https:-www.accessda"},{"kind":"regulatory-event","confidence":"high","entityId":"rituximab","entityName":"Rituximab","entityKind":"drug","route":"/drugs/rituximab/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"0 events; none dated 2026-09-28","proposed":"{ date: \"2026-09-28\", type: \"approval\", region: \"US\", note: \"RUXIENCE (RITUXIMAB-PVVR): SUPPL\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761103\" }","evidence":"PFIZER INC · SUPPL 20 · SUPPL","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761103","detected":"2026-10-14","id":"regulatory-event:rituximab:regulatoryevents:-date:-2026-09-28-type:-approval-region:-us-note:-ruxience-rituximab-pvvr-:-suppl-source:-https:-www.accessdata.fda."},{"kind":"regulatory-event","confidence":"high","entityId":"capecitabine","entityName":"Capecitabine","entityKind":"drug","route":"/drugs/capecitabine/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"0 events; none dated 2026-09-25","proposed":"{ date: \"2026-09-25\", type: \"approval\", region: \"US\", note: \"CAPECITABINE (CAPECITABINE): Labeling\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090943\" }","evidence":"RISING · SUPPL 16 · Labeling","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090943","detected":"2026-10-14","id":"regulatory-event:capecitabine:regulatoryevents:-date:-2026-09-25-type:-approval-region:-us-note:-capecitabine-capecitabine-:-labeling-source:-https:-www.accessd"},{"kind":"regulatory-event","confidence":"high","entityId":"everolimus","entityName":"Everolimus","entityKind":"drug","route":"/drugs/everolimus/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"0 events; none dated 2026-09-21","proposed":"{ date: \"2026-09-21\", type: \"approval\", region: \"US\", note: \"EVEROLIMUS (EVEROLIMUS): ORIG\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220597\" }","evidence":"NOVITIUM PHARMA · ORIG 1 · ORIG","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220597","detected":"2026-10-14","id":"regulatory-event:everolimus:regulatoryevents:-date:-2026-09-21-type:-approval-region:-us-note:-everolimus-everolimus-:-orig-source:-https:-www.accessdata.fda.go"},{"kind":"regulatory-event","confidence":"high","entityId":"everolimus","entityName":"Everolimus","entityKind":"drug","route":"/drugs/everolimus/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"0 events; none dated 2026-09-16","proposed":"{ date: \"2026-09-16\", type: \"approval\", region: \"US\", note: \"ZORTRESS (EVEROLIMUS): Labeling\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021560\" }","evidence":"NOVARTIS · SUPPL 34 · Labeling","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021560","detected":"2026-10-14","id":"regulatory-event:everolimus:regulatoryevents:-date:-2026-09-16-type:-approval-region:-us-note:-zortress-everolimus-:-labeling-source:-https:-www.accessdata.fda."},{"kind":"regulatory-event","confidence":"high","entityId":"cabozantinib","entityName":"Cabozantinib","entityKind":"drug","route":"/drugs/cabozantinib/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"1 events; none dated 2026-09-03","proposed":"{ date: \"2026-09-03\", type: \"approval\", region: \"US\", note: \"OMCAZIO (CABOZANTINIB LAURYLSULFATE): Type 5 - New Formulation or New Manufacturer\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220613\" }","evidence":"HANDA ONCOL · ORIG 1 · Type 5 - New Formulation or New Manufacturer","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220613","detected":"2026-10-14","id":"regulatory-event:cabozantinib:regulatoryevents:-date:-2026-09-03-type:-approval-region:-us-note:-omcazio-cabozantinib-laurylsulfate-:-type-5---new-formulation-o"},{"kind":"regulatory-event","confidence":"high","entityId":"fludeoxyglucose-f18","entityName":"Fludeoxyglucose F-18 (FDG)","entityKind":"drug","route":"/drugs/fludeoxyglucose-f18/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"0 events; none dated 2026-08-31","proposed":"{ date: \"2026-08-31\", type: \"approval\", region: \"US\", note: \"FLUDEOXYGLUCOSE F18 (FLUDEOXYGLUCOSE F 18): Manufacturing (CMC)\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079086\" }","evidence":"PETNET · SUPPL 31 · Manufacturing (CMC)","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079086","detected":"2026-10-14","id":"regulatory-event:fludeoxyglucose-f18:regulatoryevents:-date:-2026-08-31-type:-approval-region:-us-note:-fludeoxyglucose-f18-fludeoxyglucose-f-18-:-manufacturing"},{"kind":"regulatory-event","confidence":"high","entityId":"f-18-fdg-brain","entityName":"Fludeoxyglucose F-18 (brain metabolism)","entityKind":"drug","route":"/drugs/f-18-fdg-brain/","file":"src/data/rp/agents-neuro.ts","line":268,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/rp/agents-neuro.ts#L268","field":"regulatoryEvents","current":"0 events; none dated 2026-08-31","proposed":"{ date: \"2026-08-31\", type: \"approval\", region: \"US\", note: \"FLUDEOXYGLUCOSE F18 (FLUDEOXYGLUCOSE F 18): Manufacturing (CMC)\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079086\" }","evidence":"PETNET · SUPPL 31 · Manufacturing (CMC)","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079086","detected":"2026-10-14","id":"regulatory-event:f-18-fdg-brain:regulatoryevents:-date:-2026-08-31-type:-approval-region:-us-note:-fludeoxyglucose-f18-fludeoxyglucose-f-18-:-manufacturing-cmc-"},{"kind":"regulatory-event","confidence":"high","entityId":"durvalumab","entityName":"Durvalumab","entityKind":"drug","route":"/drugs/durvalumab/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"9 events; none dated 2026-08-31","proposed":"{ date: \"2026-08-31\", type: \"approval\", region: \"US\", note: \"IMFINZI (DURVALUMAB): Labeling\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069\" }","evidence":"ASTRAZENECA UK LTD · SUPPL 60 · Labeling","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761069","detected":"2026-10-14","id":"regulatory-event:durvalumab:regulatoryevents:-date:-2026-08-31-type:-approval-region:-us-note:-imfinzi-durvalumab-:-labeling-source:-https:-www.accessdata.fda.g"},{"kind":"regulatory-event","confidence":"high","entityId":"cabozantinib","entityName":"Cabozantinib","entityKind":"drug","route":"/drugs/cabozantinib/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"1 events; none dated 2026-08-14","proposed":"{ date: \"2026-08-14\", type: \"approval\", region: \"US\", note: \"CABOZANTINIB S-MALATE (CABOZANTINIB S-MALATE): ORIG\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213878\" }","evidence":"MSN · ORIG 1 · ORIG","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213878","detected":"2026-10-14","id":"regulatory-event:cabozantinib:regulatoryevents:-date:-2026-08-14-type:-approval-region:-us-note:-cabozantinib-s-malate-cabozantinib-s-malate-:-orig-source:-http"},{"kind":"regulatory-event","confidence":"high","entityId":"rituximab","entityName":"Rituximab","entityKind":"drug","route":"/drugs/rituximab/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"0 events; none dated 2026-07-31","proposed":"{ date: \"2026-07-31\", type: \"approval\", region: \"US\", note: \"ZIMRIXBY (RITUXIMAB-CDXX): ORIG\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761376\" }","evidence":"DR REDDYS LABS SA · ORIG 1 · ORIG","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761376","detected":"2026-10-14","id":"regulatory-event:rituximab:regulatoryevents:-date:-2026-07-31-type:-approval-region:-us-note:-zimrixby-rituximab-cdxx-:-orig-source:-https:-www.accessdata.fda.g"},{"kind":"regulatory-event","confidence":"high","entityId":"pembrolizumab","entityName":"Pembrolizumab","entityKind":"drug","route":"/drugs/pembrolizumab/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"12 events; none dated 2026-07-31","proposed":"{ date: \"2026-07-31\", type: \"approval\", region: \"US\", note: \"KEYTRUDA QLEX (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH): Labeling\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467\" }","evidence":"MERCK SHARP DOHME · SUPPL 15 · Labeling","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761467","detected":"2026-10-14","id":"regulatory-event:pembrolizumab:regulatoryevents:-date:-2026-07-31-type:-approval-region:-us-note:-keytruda-qlex-pembrolizumab-and-berahyaluronidase-alfa-pmph-:-"},{"kind":"regulatory-event","confidence":"high","entityId":"f-18-florbetaben","entityName":"Florbetaben F-18","entityKind":"drug","route":"/drugs/f-18-florbetaben/","file":"src/data/rp/agents-neuro.ts","line":104,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/rp/agents-neuro.ts#L104","field":"regulatoryEvents","current":"0 events; none dated 2026-07-22","proposed":"{ date: \"2026-07-22\", type: \"approval\", region: \"US\", note: \"NEURACEQ (FLORBETABEN F 18): Labeling\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204677\" }","evidence":"LANTHEUS · SUPPL 41 · Labeling","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204677","detected":"2026-10-14","id":"regulatory-event:f-18-florbetaben:regulatoryevents:-date:-2026-07-22-type:-approval-region:-us-note:-neuraceq-florbetaben-f-18-:-labeling-source:-https:-www.acc"},{"kind":"regulatory-event","confidence":"high","entityId":"capecitabine","entityName":"Capecitabine","entityKind":"drug","route":"/drugs/capecitabine/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"0 events; none dated 2026-07-01","proposed":"{ date: \"2026-07-01\", type: \"approval\", region: \"US\", note: \"CAPECITABINE (CAPECITABINE): Labeling\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210203\" }","evidence":"HETERO LABS LTD V · SUPPL 7 · Labeling","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210203","detected":"2026-10-14","id":"regulatory-event:capecitabine:regulatoryevents:-date:-2026-07-01-type:-approval-region:-us-note:-capecitabine-capecitabine-:-labeling-source:-https:-www.accessd"},{"kind":"regulatory-event","confidence":"high","entityId":"everolimus","entityName":"Everolimus","entityKind":"drug","route":"/drugs/everolimus/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"0 events; none dated 2026-06-30","proposed":"{ date: \"2026-06-30\", type: \"approval\", region: \"US\", note: \"EVEROLIMUS (EVEROLIMUS): ORIG\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219464\" }","evidence":"PHARMAZONE · ORIG 1 · ORIG","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219464","detected":"2026-10-14","id":"regulatory-event:everolimus:regulatoryevents:-date:-2026-06-30-type:-approval-region:-us-note:-everolimus-everolimus-:-orig-source:-https:-www.accessdata.fda.go"},{"kind":"regulatory-event","confidence":"high","entityId":"rituximab","entityName":"Rituximab","entityKind":"drug","route":"/drugs/rituximab/","file":"src/data/drugs.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/drugs.ts#L1","field":"regulatoryEvents","current":"0 events; none dated 2026-06-29","proposed":"{ date: \"2026-06-29\", type: \"approval\", region: \"US\", note: \"TRUXIMA (RITUXIMAB-ABBS): Bioequivalence\", source: \"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761088\" }","evidence":"CELLTRION INC · SUPPL 35 · Bioequivalence","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761088","detected":"2026-10-14","id":"regulatory-event:rituximab:regulatoryevents:-date:-2026-06-29-type:-approval-region:-us-note:-truxima-rituximab-abbs-:-bioequivalence-source:-https:-www.accessd"},{"kind":"trial-status","confidence":"medium","entityId":"nct03054870","entityName":"CYC-009: Technegas versus xenon-133 ventilation imaging","entityKind":"trial","route":"/trials/nct03054870/","file":"src/data/rp/agents-lung.ts","line":114,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/rp/agents-lung.ts#L114","field":"status","current":"historic","proposed":"withdrawn","evidence":"ClinicalTrials.gov overall status is TERMINATED; recorded historic. Editorial statuses (positive, negative, mixed) need the result, so this is a floor, not a verdict.","sourceUrl":"https://clinicaltrials.gov/study/NCT03054870","id":"trial-status:nct03054870:status:withdrawn","detected":"2026-10-25"},{"kind":"trial-completion","confidence":"medium","entityId":"nct06549465","entityName":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","entityKind":"trial","route":"/trials/nct06549465/","file":"src/data/trials.ts","line":1,"editUrl":"https://github.com/casadesante/Nuclide/blob/main/src/data/trials.ts#L1","field":"yearReported / calendar","current":"2027-04-20","proposed":"2027-08","evidence":"Primary completion date moved from 2027-04-20 to 2027-08; check the readout calendar entry.","sourceUrl":"https://clinicaltrials.gov/study/NCT06549465","detected":"2026-10-05","id":"trial-completion:nct06549465:yearreported-calendar:2027-08"},{"kind":"new-product","confidence":"medium","entityName":"LUTETIUM LU-177 DOTATATE","field":"new drug record","current":"(not in corpus)","proposed":"add product LUTETIUM LU-177 DOTATATE with a US approval dated 2026-09-21","evidence":"BRAVNETSA (LUTETIUM LU-177 DOTATATE)","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217060","detected":"2026-09-30","id":"new-product:lutetium-lu-177-dotatate:new-drug-record:add-product-lutetium-lu-177-dotatate-with-a-us-approval-dated-2026-09-21"},{"kind":"new-product","confidence":"medium","entityName":"CITRIC ACID ANHYDROUS AND 13C UREA","field":"new drug record","current":"(not in corpus)","proposed":"add product CITRIC ACID ANHYDROUS AND 13C UREA with a US approval dated 2026-07-24","evidence":"IDKIT:HP (CITRIC ACID ANHYDROUS AND 13C UREA)","sourceUrl":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021314","detected":"2026-09-22","id":"new-product:citric-acid-anhydrous-and-13c-urea:new-drug-record:add-product-citric-acid-anhydrous-and-13c-urea-with-a-us-approval-dated-2026-07-24"},{"kind":"trial-status","confidence":"low","entityId":"f-18-fdg-brain","entityName":"Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis (NCT02824419)","entityKind":"trial","route":"/drugs/f-18-fdg-brain/","field":"new trial record","current":"(not in corpus)","proposed":"add phase 3 trial NCT02824419 for Fludeoxyglucose F-18 (brain metabolism) with status withdrawn","evidence":"A phase 3 study of Fludeoxyglucose F-18 (brain metabolism) moved from UNKNOWN to TERMINATED (detected 2026-10-12).","sourceUrl":"https://clinicaltrials.gov/study/NCT02824419","detected":"2026-10-12","id":"trial-status:f-18-fdg-brain:new-trial-record:add-phase-3-trial-nct02824419-for-fludeoxyglucose-f-18-brain-metabolism-with-status-withdrawn"}]}